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The only currently available approach to early efficacy testing of 
tuberculosis (TB) vaccine candidates is in vivo preclinical challenge 
models. These typically include mice, guinea pigs and non-human 
primates (NHPs), which must be exposed to virulent M.tb in a 
‘challenge’ experiment following vaccination in order to evaluate 
protective efficacy. This procedure results in disease development and 
is classified as ‘Moderate’ in severity under EU legislation and UK ASPA 
licensure. Furthermore, experiments are relatively long and animals 
must be maintained in high containment level facilities, making them 
relatively costly. We describe an in vitro protocol for the direct 
mycobacterial growth inhibition assay (MGIA) for use in the macaque 
model of TB vaccine development with the aim of overcoming some of 
these limitations. Importantly, using an in vitro assay in place of in vivo 
M.tb challenge represents a significant refinement to the existing 
procedure for early vaccine efficacy testing. Peripheral blood 
mononuclear cell and autologous serum samples collected from 
vaccinated and unvaccinated control animals are co-cultured with 
mycobacteria in a 48-well plate format for 96 hours. Adherent 
monocytes are then lysed to release intracellular mycobacteria which 
is quantified using the BACTEC MGIT system and colony-forming units 
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determined relative to an inoculum control and stock standard curve. 
We discuss related optimisation and characterisation experiments, 
and review evidence that the direct NHP MGIA provides a biologically 
relevant model of vaccine-induced protection. The potential end-users 
of the NHP MGIA are academic and industry organisations that 
conduct the assessment of TB vaccine candidates and associated 
protective immunity using the NHP model. This approach aims to 
provide a method for high-throughput down-selection of vaccine 
candidates going forward to in vivo efficacy testing, thus expediting 
the development of a more efficacious TB vaccine and offering 
potential refinement and reduction to the use of NHPs for this 
purpose.
Keywords 
3Rs, refinement, non-human primate, macaque, mycobacterial growth 
inhibition assay, tuberculosis, vaccines
 This article is included in the NC3Rs gateway.
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1.0 Introduction
Approximately 1 in 4 people globally are infected with tuber-
culosis (TB), with 10 million new infections and 1.4 million 
deaths reported in 20191. This serious public health threat is 
further exacerbated by the spread of multi- and extensively-
drug resistant strains of the causative agent, Mycobacterium 
tuberculosis (M.tb)2. An efficacious vaccine is widely acknowl-
edged to be the most effective intervention strategy. The Bacil-
lus Calmette-Guérin (BCG) vaccine, first introduced in 1921, 
remains the only currently-licenced TB vaccine. Although pro-
tective in infants against severe forms of TB disease, BCG 
affords extremely variable levels of protection against the most 
common and infectious form of TB, pulmonary disease, in 
adults3. BCG-induced protection against pulmonary TB is 
lowest in regions close to the equator such as sub-Saharan 
Africa and India where an effective vaccine is most desperately 
needed3. However, development of a successful TB vaccine 
is severely hampered by the lack of a validated correlate or 
biomarker of protection4. It remains unclear which aspects of the 
immune response confer protection from TB disease, and 
therefore which parameters to target with a vaccine and to 
assess as a reliable measure of protective efficacy.
1.1 Existing approaches to early evaluation of TB 
vaccine efficacy
In the absence of a validated immune correlate of protection 
from TB, the only currently available approach to early efficacy 
testing of TB vaccine candidates is the use of preclinical 
‘challenge’ (infection) models. Animals used typically include 
mice, guinea pigs and non-human primates (NHPs). In vivo 
testing offers the obvious and unparalleled advantage of mod-
elling the complexities of biological systems (the immune 
system representing one of the most complex and systemic of 
all) in the context of their natural microenvironment over time. 
NHPs are considered the most representative model for 
human TB due to their anatomical and physiological similari-
ties, natural susceptibility to M.tb infection and comparable 
pathological and clinical outcomes5. Rhesus and cynomolgus 
macaques in particular are widely used in TB vaccine stud-
ies as BCG vaccination offers partial and quantifiable protection 
against M.tb challenge in these species6–10. There has been recent 
emphasis on the use of NHPs as the ‘gatekeeper’ for progres-
sion of TB vaccine candidates to clinical trials, and the numbers 
used in the field are increasing11.
In order to evaluate the protective efficacy of a candidate 
TB vaccine, animals must be exposed to virulent M.tb in 
a ‘challenge’ experiment following vaccination. Infection 
with M.tb results in disease development and is classified as 
‘Moderate’ in severity under EU legislation and UK ASPA 
licensure12. Welfare considerations include the infection proc-
ess itself, disease symptoms, and the definition of humane end-
points. A study assessing the lifetime experience of macaques 
found that the combined welfare assessment score increased 
from <10 to >50 following M.tb challenge, reflecting a decline 
in procedural, physical, psychological and environmental 
welfare13. Other limitations of the NHP challenge model in 
TB vaccine testing include the long and costly nature of such 




needed effective TB vaccine through rapid down-
selection of candidates at an early stage.
• Tractable system for the exploration of immune 
mechanisms underlying the control of mycobacterial 
growth.
• Opportunity to biologically validate the direct PBMC 
MGIA through correlation with protection from in vivo 
M.tb challenge on an individual animal basis.
3Rs benefits 
• Refining early efficacy testing of TB vaccine candidates 
by using the MGIA in place of in vivo infection with 
pathogenic M.tb.
• Reducing the number of NHPs used in TB vaccine 
testing and associated immunology studies by down-
selecting the number of candidates going forward to 
in vivo testing and by allowing the testing of multiple 
conditions using cells from a single group.
• Bridging of the assay to use in target species including 
humans to replace the use of preclinical models in 
some settings. 
Practical benefits 
• Measures of vaccine efficacy obtained more rapidly than 
in vivo	M.tb challenge studies (2 weeks vs. 12 weeks 
routinely required for in vivo challenge). Quantification 
using the BACTEC MGIT system also more rapid than 
conventional colony counting on agar.
• Negates the need for high containment animal facilities 
required for in vivo	M.tb challenge.
• More cost-effective, much lower resource requirement 
and less technically challenging than in vivo	M.tb	
challenge studies in NHPs.
Current applications 
• Assessing the BCG vaccine-induced response as a 
benchmark and comparing between different routes of 
administration37.
• Comparing outcomes with levels of protection from 
in vivo	M.tb or BCG challenge to determine biological 
validity37.
•	 Applying to other aspects of TB research, such as 
assessing ability to control mycobacterial growth 
following M.tb infection and comparisons between 
species36.
• Exploring underlying immune mechanisms including 
associations between growth inhibition and various 
cell type frequencies, specific antibodies, and baseline 
characteristics35, [Tanner R, unpublished data].
Potential applications 
• Assessing protective efficacy of novel TB vaccine 
candidates.
• Understanding associated immune mechanisms of 
protection.
• Measuring vaccine potency, lot-to-lot consistency and 
stability.
• Adaptation for use with other pathogens (e.g. S. aureus).
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One potential alternative or complementary tool for assess-
ing vaccines is functional in vitro assays such as growth inhibi-
tion assays (GIAs) as a potential surrogate measure of vaccine 
efficacy. Such assays aim to provide unbiased read-outs of 
the combined effects of the host immune response, strain 
virulence and influences of interventions. They have been applied 
with some degree of success to a range of other disease mod-
els including HIV, malaria and meningitis15–17. A number of 
mycobacterial GIAs (MGIAs) for TB have been previ-
ously described in the literature, including the use of 
reporter strains in whole blood18,19 and primary or secondary 
lymphocyte/monocyte co-cultures in humans20,21, bone marrow 
macrophage/splenocyte cultures in mice22,23, and cattle periph-
eral blood mononuclear cell (PBMC)24,25. These have been com-
prehensively reviewed elsewhere26. However, in all cases such 
assays are technically challenging and limited follow-up work 
has been conducted to qualify an MGIA that could be trans-
ferred across laboratories using a standardised, reproducible 
method.
We have previously worked to optimise and standardise a 
simplified MGIA (known as the ‘direct MGIA’) for use in 
humans and mice, adapted from methods originally described by 
Wallis et al., using the BACTEC MGIT mycobacterial quan-
tification system27–29. Applying this approach, we have dem-
onstrated a BCG vaccine-induced effect in these species30–32, 
and an association with in vivo protection from mycobacterial 
challenge has also been described33,34. Importantly, preclinical 
MGIAs represent a potential alternative to the in vivo M.tb 
challenge step in early TB vaccine testing: a major refinement 
which is particularly important for NHPs due to the additional 
welfare and behavioural considerations that apply when 
using these species in medical research. Furthermore, the NHP 
model represents a unique opportunity for biological valida-
tion of the assay against direct measures of in vivo protection, 
as discussed below, permitting bridging to use in other species 
including humans. We present a protocol for the first example 
of an NHP MGIA using in vitro cell co-culture, adapted from 
our direct MGIA methods described in humans and mice, 
with the aim of refining and expediting early TB vaccine 
testing35–37.
1.2 3Rs relevance
1.2.1 Refinement. The main 3Rs objective of the direct 
NHP MGIA is to provide a potential refinement to the proc-
ess of early TB vaccine testing in NHP models through 
offering a functional in vitro assay as an alternative to in vivo 
infection with pathogenic M.tb. If the MGIA were applied in 
place of in vivo M.tb infection, animals would still be required 
for vaccination, but blood samples could be taken before and at 
various time-points after vaccination, and ability to control 
growth of mycobacteria assessed in vitro without the need for 
M.tb infection of the animals. Lifetime experience would 
be improved and the severity rating for the experiment 
would be downgraded from ‘Moderate’ to ‘Mild’ under EU 
legislation12,13,38.
1.2.2 Reduction. A successful, validated MGIA could be used 
to test and down-select experimental TB vaccine candidates 
at an early stage of development, reducing the number going 
forward to virulent M.tb challenge experiments and therefore 
the number of animals used. It would also reduce the number 
of animals required as multiple conditions (such as control of 
different mycobacterial strains or contribution of different 
immune parameters) could be tested using samples from a single 
group of vaccinated animals. It is increasingly acknowledged 
that the level of protection conferred by a TB vaccine candidate 
may be influenced by the M.tb strain/s prevalent in the 
geographical region in which it is being tested39,40. 
Furthermore, preclinical testing of TB vaccine candidates gen-
erally use standardised (and sometimes attenuated) laboratory 
strains of M.tb as challenge agents. It is prudent to test vaccine 
efficacy against a range of M.tb strains or clinical isolates to 
ensure widespread applicability. Using an in vivo challenge model, 
this would necessitate an additional group of experimentally 
infected animals for each strain. The NHP MGIA allows sam-
ples from a single group of animals to be assessed for ability 
to control multiple mycobacterial strains, particularly as there 
are no restrictions on the inoculum, unlike for assays which 
use reporter strains for example.
The MGIA also offers a tractable model for the exploration 
of underlying immune mechanisms involved in the control of 
mycobacterial growth. Cell types of interest may be depleted, 
purified and added back at different concentrations, pathways 
interrupted, receptors blocked and so forth to elucidate those 
of importance. The ability to conduct such experiments in vivo, 
for example adoptive transfer, is limited and requires large num-
bers of animals. Using the MGIA, multiple conditions can be 
explored with a sample set from a single group of animals, in 
contrast to the additional groups required for equivalent 
in vivo experiments with the associated impacts on disease 
severity. To illustrate, a hypothetical in vivo experiment designed 
to test a novel vaccine candidate would require minimum 
group sizes of 8 macaques to detect a nine-AU reduction 
in total pathology given a group standard deviation of 5.8 with 
a power of 80% and an α of 0.05. Including a naïve control 
group, a BCG-vaccinated group as a benchmark, and a group 
for the novel vaccine candidate, testing efficacy against three 
strains of M.tb would require three groups for each condi-
tion (as each animal can only be challenged with one strain) = 
72 animals vs. 24 for in vitro assessment using the NHP MGIA 
(Table 1). This represents a 3-fold reduction in the number 
of animals used.
1.2.3 Replacement. As described, our direct MGIA method has 
also been optimised for use with human cells29. However, the 
biological relevance of the direct MGIA, as for any potential 
correlate of protection, can only be confirmed by demonstrat-
ing an association with in vivo protection from either controlled 
or natural infection or disease. While controlled infection with 
BCG may be used as a potential surrogate in human chal-
lenge studies, virulent M.tb cannot ethically be used33. The NHP 
model provides an opportunity to validate the assay against 
protection from M.tb as well as BCG infection, allowing greater 
confidence in the relevance of the human assay such that 
preclinical models such as mice, guinea pigs and NHP may 
ultimately be replaced with human samples in some settings. 
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Furthermore, the MGIA could be applied in the measurement 
of vaccine potency, lot-to-lot consistency and stability as an 
alternative to in vivo infection experiments. The 3Rs relevance 
of the NHP MGIA is summarised in Figure 1.
1.3 Potential end-users
The potential end-users of the NHP MGIA are academic and 
industry organisations that conduct the assessment of TB 
vaccine candidates and associated protective immunity using 
the NHP model. This currently includes groups in Europe such 
as the UK, Sweden and the Netherlands; Pittsburgh, Chicago, 
Boston, California, New Orleans, Texas and Seattle in the USA; 
Osaka, Japan; Wuhan, China; and the Philippines among 
others41. Peña et al. reviewed the major NHP TB studies pub-
lished between 2001 and 2014. During this period, the mean 
number of publications increased from 1 per year in 2001–2007 
to 4 per year in 2007–2014. The mean number of animals used 
per publication was 14 for rhesus macaques (range 3–32) and 
20 for cynomolgus macaques (range 2–44). For TB vaccine-
related studies specifically, the mean number of animals used was 
20 (range 12–32)41. Conducting a literature search for the 
time-period 2019–2020 using the Google Scholar search terms 
‘tuberculosis’ and ‘macaque’, and excluding results relating to 
TB diagnostics or drugs, and/or SIV coinfection, we identified 
21 publications reporting NHP studies of TB vaccines and/or 
TB immunology employing a mean of 27 animals (range 6–75), 
Figure 1. The 3Rs relevance of the NHP MGIA.
Table 1. A hypothetical experimental design demonstrating the numbers of 
animals required for in vivo challenge vs. in vitro MGIA evaluation.
Method No. of animals 
per group
No. for vaccine 
candidate









1 x vaccine X
x 3 strains = 24	
x 3 strains = 24	
x 3 strains = 24
72





1 x vaccine X
x 3 strains = 8	
x 3 strains = 8	
x 3 strains = 8
24
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the majority of which involved challenge with M.tb. This illus-
trates a trend towards increased use of NHPs in the field and 
larger group sizes. Widespread adoption of a validated NHP 
MGIA could significantly reduce the number of animals under-




The reagents and equipment required for the direct NHP MGIA 
are described in Table 2 and Table 3 respectively. It is not 
essential to use a specific supplier of reagents or equipment 
unless it is specified in the table.
2.2 Samples
2.2.1 NHP samples. Stored samples used in the optimisation 
experiment shown in Figure 6 were collected from n=7 female 
rhesus macaques of Indian genotype aged 14–15 years as part 
of a study of BCG vaccination conducted at Public Health 
England (PHE) in the UK. Design and procedures of the original 
study were approved by the Public Health England Animal Wel-
fare and Ethical Review Body and authorized under an appro-
priate UK Home Office project license. Animals were housed 
in compatible social groups in accordance with the Home Office 
(UK) Code of Practice for the Housing and Care of Animals 
Used in Scientific Procedures (1989) and the National Centre for 
Refinement, Reduction and Replacement (NC3Rs) Guidelines on 
Primate Accommodation, Care and Use, August 2006 (NC3Rs, 
2006). They were provided with enrichment in the form of 
food and non-food items on a daily basis; animal welfare was 
monitored daily. Animals were captive-bred for research pur-
poses, were obtained from established breeding colonies at PHE, 
were healthy and had not been used previously for experimen-
tal procedures. Animals were sedated by intramuscular (IM) 
injection of ketamine hydrochloride (Ketaset, 100 mg/ml, Fort 
Dodge Animal Health Ltd, Southampton, UK; 10 mg/kg) for 
procedures requiring removal from their housing. Animals were 
weighed, had rectal temperature measured and were examined 
for gross abnormalities whenever procedures (vaccination, blood 
sample collection) were conducted. There were no adverse 
events, and no humane endpoints for this study as it did not 
involve M.tb challenge.
2.2.2 Human samples. Samples used in the optimisation experi-
ments shown in Figure 5 and Figure 7 were obtained from 
volunteers at the Jenner Institute, Oxford, in accordance 
with University of Oxford policy. All human samples were 
collected in accordance with the ethical principles set forth 
in the Declaration of Helsinki as agreed by the World Medi-
cal Association General Assembly (Washington 2002), ICH 
Good Clinical Practice (GCP) and local regulatory requirements; 
volunteers gave written informed consent.
2.3 Design of optimisation experiments
For the experiments shown in Figure 5, the experimental unit 
was a co-culture containing 1 × 106 cells from a single volunteer 
Table 2. Reagents required for the direct PBMC NHP MGIA.
Reagents
RPMI-1610 (serum-free)
RPMI-1640 medium with HEPES modification
L-glutamine (200mM 100X)
Sodium Pyruvate
Foetal Bovine Serum (FCS)
Benzonase nuclease (25U/µl)
BBL MGIT tubes containing 7ml media (Becton Dickinson)
PANTA/enrichment supplement for MGIT tubes (Becton Dickinson)
Cell culture grade sterile water
Standardised BCG Pasteur stock (Aeras)
Phosphate Buffered Saline (PBS) 
Tween 80
Middlebrook 7H10 Agar base
Oleic Albumin Dextrose Catalase (OADC) supplement
Glycerol
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to ensure all variables were constant apart from the one 
under investigation (treatment of mycobacterial stock). The 
sample sizes were duplicate co-cultures for Figure 5A as this 
was a time-course with repeated measures of a single condi-
tion, and (n=6) replicate co-cultures for Figure 5B as this was a 
group-wise comparison of different stock conditions. For the 
experiments shown in Figure 6 and Figure 7 , the experimental unit 
was an individual macaque (n=7) or an individual volunteer (n=6) 
respectively each tested in duplicate; these were group-wise 
comparisons of co-cultures containing different serum/plasma 
conditions. Samples were not selected but were used accord-
ing to availability and recovery of a sufficient number of PBMC 
post-thawing and a sufficient volume of serum/plasma. No 
data points were excluded from the analysis. Minimum sam-
ple size (n=6) for these experiments was calculated based on the 
effect size of 0.2 log
10
 CFU (colony-forming units) observed in 
previous MGIA experiments considered to be biologically 
relevant (given matched measures of in vivo efficacy) and esti-
mates of variability within a group with a power of 80% and 
an α of 0.05. Cells were allocated to conditions by pipetting 
to mix and adding to conditions in repeated sequence where rel-
evant (Figure 5B). Operator blinding was not possible because 
the comparisons required operator interventions in the labora-
tory and the BCG status of the animals was not relevant to these 
experiments. In all cases, the outcome measured was effect of 
co-culture condition (stock treatment, plasma vs. serum, or col-
lection/treatment of serum) on mycobacterial growth over the 96 
hour co-culture period, as measured by MGIT time-to-positivity 
(TTP) and/or converted to log
10
 CFU normalised to the direct-
to-MGIT inoculum control. Statistical analysis was conducted 
using GraphPad Prism v.7, and data was analysed using non- 
parametric tests due to the small sample sizes; multi-group data 
was corrected for multiple comparisons using Dunn’s test (all 
conditions vs. all other conditions). Following confirmation of 
normality in the distribution of differences between paired 
measurements, the Bland-Altman method was used to compare 
MGIA outcomes between serum and plasma in Figure 6. 95% 
confidence intervals for the Bland-Altman limits of agreement 
were calculated using the methods described by Carkeet42.
2.4 Mycobacterial Growth Inhibition Assay
2.4.1 PBMC preparation. Cryopreserved PBMC were rap-
idly thawed in a water bath at 37°C until a small amount of fro-
zen material remained. Samples were gradually added to 10ml 
RPMI (containing 10% foetal calf serum and 2mM L-glutamine) 
using a Pasteur pipette. The cryovial was rinsed using 1ml of 
fresh medium and added to the corresponding tube, which was 
then centrifuged at 350 g for 7 min. Supernatants were 
removed by inversion and cells resuspended at an approximate 
concentration of 2 × 106 cells per ml of RPMI (containing 10% 
foetal calf serum and 2mM L-glutamine) and 2µl/ml of 25 U 
benzonase added to each tube. Cells were rested at 37°C for 2 h 
with 5% CO
2
 before counting using an automated CASY 
cell counter.
2.4.2 MGIA. For the human MGIA experiments shown in 
Figure 5 and Figure 7, 600µl RPMI (containing 2mM L-glutamine 
and 25mM HEPES) seeded with 1 × 106 PBMC and ~100 CFU 
(Figure 5) or ~500 CFU (Figure 7) BCG Pasteur was added 
to duplicate 2ml screw-cap tubes. The co-cultures were 
Table 3. Equipment required for the direct PBMC 
NHP MGIA.
Equipment
BACTEC MGIT 320/960 instrument (Becton Dickinson)
37°C water bath
Centrifuge and microcentrifuge
37°C incubator with CO2
Cell counter/microscope and associated equipment





Sterile borosilicate solid-glass beads (1mm)
50ml falcon tubes
Petri dishes (60mm)
P20, P200 and P1000 pipettes and filter tips
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incubated on a 360° rotator at 37°C for 96 hours, after which time 
tubes were microcentrifuged at 15,300 g for 10 minutes and the 
supernatant carefully removed by pipetting. Cells were lysed 
with the addition of 500µl sterile water and the tubes pulse- 
vortexed at 0, 5 and 10 minutes. For the NHP direct PBMC 
‘in-plate’ MGIA, shown in Figure 6, 3 × 106 PBMC and ~500 
CFU BCG Pasteur in a total volume of 480µl RPMI (con-
taining 2mM L-glutamine and 25mM HEPES), plus 120µl 
autologous serum or plasma matched to animal were added 
per well of a 48-well plate (total volume 600µl per well). 
Co-cultures were incubated at 37°C for 96 hours with CO
2
 
and then transferred to 2ml screw-cap tubes and centrifuged at 
15,300 g for 10 minutes. During this time, 500µl sterile water 
was added to each well to lyse adherent monocytes and release 
intracellular mycobacteria. Supernatants were carefully removed 
from the 2ml screw-cap tubes by pipetting, and water from 
the corresponding well added to the remaining pellet. In all 
cases, tubes were pulse vortexed and lysates transferred to a 
BACTEC MGIT tube supplemented with PANTA antibiot-
ics (polymyxin B, amphotericin B, nalidixic acid, trimethoprim 
and azlocillin) and OADC enrichment broth (Becton Dickinson, 
UK) before being placed on the BACTEC 960 machine 
(Becton Dickinson, UK) and incubated at 37°C until the detec-
tion of positivity by fluorescence. On day 0, duplicate direct- 
to-MGIT control tubes were set up by inoculating supplemented 
BACTEC MGIT tubes with the same amount of mycobacte-
ria as the samples. The TTP read-out can be converted to log
10
 
CFU using stock standard curves of TTP against inoculum vol-
ume and CFU. ‘Normalised mycobacterial growth’ is equal to 
(log
10
 CFU of sample – log
10
 CFU of growth control).
3.0 Detailed protocol for the NHP direct PBMC 
MGIA
Note: All work must be performed under sterile tissue culture 
conditions in a Class II biological safety cabinet and filter tips 
should be used throughout.
3.1 At least three weeks ahead of time, generate a 
standard curve as follows (summarised graphically in 
Figure 2)
3.1.1 Thaw one vial of BCG Pasteur (or other desired 
mycobacterial strain) at room temperature.
Note: We recommend a standardised stock of BCG Pasteur 
produced by Aeras specifically for use in the direct MGIA 
for consistency. Other stocks may be used but clumping may 
compromise assay reproducibility and sensitivity; if this is the 
case, vortexing with ~50 × 1mm borosilicate glass beads for 
2 minutes prior to inoculation is recommended to reduce 
clumping.
Note: If M.tb strains are used, all work should be conducted 
in an appropriate high biosafety containment laboratory.
3.1.2 Prepare 6 sterile 2ml screw-cap tubes by adding 1.35ml 
sterile PBS to each tube and labelling 1 to 6.
3.1.3 Add 150µl neat BCG Pasteur stock to tube 1, mix by pipet-
ting up and down, and then take 150µl from this tube and add 
to tube 2, and so on to make a 1:10 dilution series.
Note: The contents of each tube should be mixed thoroughly 
by pipetting up and down several times before adding to the 
next tube in the dilution series.
3.1.4 Prepare MGIT supplement medium by pouring one bot-
tle of OADC growth enrichment into one bottle of lyophilised 
PANTA. Mix by inverting several times until fully dissolved.
Note: Enrichment media should be used on day of 
reconstitution.
3.1.5 Add 800µl of supplement medium to each of 14 
BACTEC MGIT tubes (2 per standard curve dilution).
Note: Tubes are oxygen-enriched and time without caps 
should be minimised.
Note: MGIT tubes should be used on day of supplementation 
and should not be stored following supplementation.
3.1.6 Add 500µl of neat BCG stock directly to each of two 
supplemented MGIT tubes and invert to mix.
3.1.7 Add 500µl from each of dilution tubes 1–6 to MGIT 
tubes in duplicate and invert to mix.
Note: After addition of BCG, MGIT tubes should be 
capped immediately and inverted to mix.
3.1.8 Scan MGIT tube barcodes on the BACTEC MGIT 
machine and place in the indicated slots.
Note: The machine will generate an alarm when tubes reach 
a predefined level of fluorescence (indicating that mycobac-
teria have utilised the oxygen previously quenched to the 
fluorochrome). Positive tubes will be indicated by flashing lights 
and can be scanned out of the machine and the corresponding 
TTP recorded.
3.1.9 Divide four 7H10 agar plates into quadrants and spot 
3 × 20µl from the neat vial and each dilution into a quadrant on 
each of two plates. Leave plates to dry in the Class II cabinet 
before sealing with parafilm and placing in a CO
2
 incubator at 
37°C. Plates should be checked after 2 weeks and daily hence-
forth; as soon as colonies are visible they should be counted 
and the number of spots recorded for each dilution and 
averaged across the 3 replicates.
3.1.10 Generate a standard curve by plotting TTP against 
CFU for each input volume and use regression analysis to 
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Figure 2. Generation of a stock standard curve (created with BioRender.com).
obtain an equation for the curve. CFU should be fitted using 
a semi-log line, and log
10
 CFU with a linear regression. Solve 
the equation describing the line for X: Y = A*X+B -> 
X =(Y-B)/A where A = slope and B = y-intercept). By insert-
ing the TTP (=Y) for any given sample, the corresponding 
number of CFU (or log
10
 CFU) can now be calculated. Further 
information including a sample MGIT read-out and standard 
curve have previously been provided by Zelmer et al.43.
3.2 MGIA day 0: Assay set-up (summarised graphically 
in Figure 3)
3.2.1 Thaw cryopreserved cells by holding the lower portion 
of the vial in a 37°C water bath.
Note: Vials should be removed from the water bath when a 
small amount of frozen material is still visible and the outside 
of the vial should be cleaned with 70% ethanol.
3.2.2 Pipette cells up and down gently using a Pasteur pipette 
and gradually add to 10ml RPMI (with L-glutamine and 
sodium pyruvate but NO antibiotics (pen/strep)).
Note: Prepare labelled tubes with 10ml media before beginning 
the thawing process.
3.2.3 Rinse out the cryovial contents with 1ml of fresh medium 
and add the remaining cells.
3.2.4 Centrifuge at 350 g for 7 minutes.
3.2.5 Pour off supernatant and resuspend cells at approximately 
2 – 3 × 106 cells per ml of RPMI (with L-glutamine and sodium 
pyruvate but no antibiotics (pen/strep)).




3.2.7 Count viable cells using standard methods (such as a 
haemocytometer or automated cell counter) and resuspend at 
10 × 106 cells per ml of RPMI (with 2mM L-glutamine 
and 25mM HEPES but NO antibiotics (pen/strep)).
3.2.8 Place 300µl of cell mix (containing 3×106 PBMC) into 
labelled wells of a 48-well plate.
Note: Replicate cultures should be performed if sufficient cells 
are available, but replicates have been demonstrated to be 
consistent (coefficient of variation (CV) <10%)37 such that a single 
culture is acceptable where cell availability is limiting.
Note: Do not use wells on the outside rows/columns of the 
48-well plate for cultures. These should contain 600μl of 
RPMI medium only.
3.2.9 Add 120µl of non-heat inactivated autologous serum or 
plasma matched to the animal and time-point (to give a final 
concentration of 20%).
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Figure 3. Day 0 MGIA set-up (created with BioRender.com).
Note: Serum should be kept sterile or syringed through 
a 0.2μM cellulose acetate filter prior to use.
Note: 10% filtered pooled human AB serum may be used if 
autologous serum is not available, but will not capture the 
influence of serum factors such as antibodies on control 
of mycobacterial growth.
Note: Autologous plasma may be used if serum in unavailable 
(see section 4.1.2.3); if plasma is viscous, it may be warmed 
in a 37°C incubator.
Note: Ensure serum/plasma is mixed well (for example 
by briefly vortexing) before adding.
3.2.10 Thaw BCG stock at room temperature and prepare to 
the correct concentration in RPMI (with 2mM L-glutamine 
and 25mM HEPES but NO PEN/STREP). The appropriate dilu-
tion factor will depend on the particular stock, but should be 
calculated using the standard curve generated in section 3.1 
to give a concentration of 500 CFU (equivalent to a TTP of 
approximately 8.5 days) per 180µl of media for each co-culture 
well required.
Note: If stock is highly concentrated, the stock should be 
diluted in several steps (e.g. serial 1:10 dilutions) to avoid 
pipetting very small volumes.
Note: If other mycobacterial species or strains are used, 
the optimum multiplicity of infection (MOI) for each strain 
should be determined prior. For an example MOI optimisation 
experimental design, please refer to Zelmer et al.32.
3.2.11 Add 180µl (containing 500 CFU) of the BCG final 
preparation to each sample well.
3.2.12 Incubate the 48-well plates in a CO
2
 incubator 
at 37°C for 96 hrs (4 days).
3.2.13 Supplement one MGIT tube with 800µl PANTA/ 
enrichment to produce supplemented Middlebrook 7H9. Decant 
the contents into a fresh falcon tube for use in step 3.2.15.
Page 10 of 23
F1000Research 2021, 10:257 Last updated: 04 MAY 2021
Figure 4. Day 4 MGIA processing (created with BioRender.com).
3.2.14 Supplement 2 further MGIT tubes with 800µl PANTA/
enrichment. These are the direct-to-MGIT inoculum controls.
3.2.15 Add an equal volume (180µl) of diluted BCG Pas-
teur prepared in step 3.2.10 to each of the 2 direct-to-MGIT 
controls. Using the extra supplemented Middlebrook 7H9 pro-
duced in step 3.2.13, make up the added volume to 500µl (so if 
180µl of BCG preparation is added, add an additional 320µl 
of supplemented Middlebrook 7H9). Invert to mix, scan the 
barcode and place on the BACTEC MGIT machine. Refer to 
section 3.1.8 and section 3.1.10 for obtaining results.
3.3 MGIA day 4: Assay processing (summarised 
graphically in Figure 4)
3.3.1 Before harvesting co-cultures, supplement 1 MGIT 
tube per culture well with 800µl PANTA enrichment and label.
3.3.2 Pipette the cultures in the well up and down three 
times, collect the liquid and transfer to a 2ml screw-cap tube.
3.3.3 Microcentrifuge tubes at 15,300 g for 10 minutes.
3.3.4 Add 500µl of sterile, tissue culture-grade water to each 
well, and incubate at room temperature for at least 5 minutes.
3.3.5 Remove 500µl of supernatant from the 2ml tubes, ensur-
ing the pellet remains intact. Supernatant can be discarded unless 
required for later cytokine analysis.
Note: Pellets appear as a small ‘smudge’ and are easily dis-
turbed; particular care should be taken during this step to avoid 
disturbing the pellet.
3.3.6 Pipette the water in the wells up and down ~8 times to 
detach monocytes that have attached to the bottom of the well 
(avoid forming bubbles as far as possible) and completely 
remove the water from the well, transferring it to the 
corresponding tube containing the cell/BCG pellet.
3.3.7 Pulse vortex for 1–2 seconds, and add all of the sample 
from the 2ml tube to the corresponding MGIT tube. Use some 
media from the MGIT tube to rinse the 2ml tube and add back 
to the same MGIT tube.
3.3.8 Invert all MGIT tubes to mix and place on the BACTEC 
MGIT instrument until positivity is reached (see section 3.1.8).
3.4 Data processing and reporting
3.4.1 Record TTP for control and sample MGIT tubes and 
convert to log
10
 CFU values using the corresponding stock 
standard curve generated in section 3.1.
Note: Stored samples should be batched as far as possible; if 
more than one batch or experiment is to be directly compared, 
each sample read-out should be normalised to its correspond-
ing direct-to-MGIT control (by subtracting the log
10
 CFU of the 
control from the log
10
 CFU of the sample) to account for 
differences in input inocula between assay runs.
4.0 Results
4.1 Optimisation and characterisation studies
A range of optimisation and characterisation studies were 
conducted during the development of the direct MGIA. 
While some of these were performed using human cells (where 
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Figure 5. Mycobacterial stock preparation. The effect of A) time from thawing to inoculation and B) de-clumping method for mycobacterial 
stock on BACTEC MGIT time to positivity (TTP) were determined using in-tube co-cultures of human PBMC and BCG Pasteur. For A), points 
represent the mean of n=2 duplicate co-cultures with the standard error of the mean (SEM). For B), points represent n=6 individual replicate 
co-cultures, boxes indicate the median value with the interquartile range and whiskers indicate the minimum and maximum values. A 
Kruskal-Wallis test was performed with a Dunn’s multiple comparisons test, where * indicates a p-value of <0.05, ** indicates a p-value of 
<0.01, and *** indicates a p-value of <0.001.
Figure 6. Bland-Altman plot comparing serum vs. plasma in the NHP direct MGIA. The NHP PBMC direct MGIA was conducted using 
either autologous serum or plasma for n=7 macaques. Co-cultures were performed in duplicate where sufficient numbers of cells were 
recovered. The solid green line indicates the mean difference between measurements and the dotted red line indicates the upper and 
lower limits of agreement (mean difference ± 1.96 standard deviation of the difference) with red vertical bars showing the 95% confidence 
intervals for the limits of agreement.
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Figure 7. Effect of using heat inactivated serum or collecting blood in EDTA vacutainers. The effect of heat inactivating (HI) pooled 
human serum or of collecting blood in EDTA tubes was assessed using in-tube co-cultures for n=6 human PBMC. Points represent individuals 
with the mean of two replicate co-cultures, boxes indicate the median value with the interquartile range and whiskers indicate the minimum 
and maximum values. A Friedman test with Dunn’s correction for multiple comparisons was used where ** indicates a p-value of <0.01. TTP 
= MGIT time to positivity, HI = heat inactivated.
specified) for reasons of ethics and sample availability, out-
comes have informed the development of the macaque assay 
protocol.
4.1.1 Mycobacterial stock. In order to minimise the variabil-
ity associated with low-titre mycobacterial inocula, two stock 
parameters were assessed: a) time from thawing to inoculation 
and b) de-clumping methods. Mycobacteria were thawed and 
added to duplicate human PBMC co-cultures every hour for 
5 hours after resting on the bench at room temperature. Myco-
bacterial viability showed a progressive, albeit modest, decrease 
for the first 3 hours, before beginning to recover at 4 hours 
(Figure 5A). Six methods of de-clumping were compared using 
6 replicate in-tube co-cultures containing cells from the same 
human sample for each method: 1) vortexing for 5 minutes 
on the highest speed, 2) standing on the bench for 5 minutes 
to allow clumps to settle and then removing only the top fraction, 
3) centrifuging at a low speed to bring clumps down and then 
removing only the top fraction, 4) sonicating for 2 minutes, 
5) vortexing with 1mm borosilicate solid-glass beads for 
2 minutes, and 6) syringing through a 5µM cellulose acetate 
filter.
Mycobacterial recovery was highest using the glass beads 
method, while other methods (particularly centrifuging and fil-
tering) resulted in some loss of mycobacteria. BCG growth 
was significantly higher (lower TTP) following vortexing 
with glass beads compared with centrifuging or filtering 
(p=0.0002, Δ mean TTP = 90 hours; and p=0.008, Δ mean TTP = 
83 hours respectively; Kruskal Wallis with Dunn’s multiple com-
parisons test, p=0.0002, Figure 5B). Reproducibility between 
replicates was greatest for glass beads and filtering (coefficient 
of variation, CV = 2.2% and 1.2% respectively), and poorest 
for vortexing (CV = 13%). Based on these findings, we recom-
mend that mycobacterial stocks suffering from clumping should 
be vortexed with sterile 1mm borosilicate glass beads (Sigma 
Aldrich, UK) for 2 minutes prior to inoculation, and that 
inoculation should be conducted as soon after thawing as 
possible.
M.tb is the pathogen of interest and may be used as the myco-
bacterial inoculum in the direct NHP MGIA; indeed we have 
demonstrated a BCG-vaccine induced effect and a correlation 
with protection from in vivo mycobacterial challenge using whole 
blood from macaques co-cultured with M.tb H37Rv37. 
However, a similar MGIA kinetic was observed whether BCG 
or M.tb was used as the inoculum, with a correlation between 
the two measures37. Such an association has also been 
reported in the human direct MGIA28,44. In the NHP direct 
MGIA, we observed improved intra-assay reproducibility using 
M.tb compared with BCG which may have improved ability 
to detect a correlation with in vivo protection. However, using 
BCG increased sensitivity to observe a vaccine response (post- 
vaccination growth – baseline growth), and it was this measure 
that correlated most consistently with in vivo protection in our 
studies37. On balance, we chose to pursue assay development 
using BCG to aid transferability by negating the need for high 
containment level laboratory facilities.
4.1.2 Co-culture conditions
4.1.2.1 Whole blood vs. PBMC
While whole blood may represent the most ex vivo sample, we 
previously reported a correlation between mean corpuscular 
haemoglobin (Hb) and mycobacterial growth in the human 
direct MGIA35. Furthermore, addition of either Hb or ferric 
ammonium citrate to both human and macaque PBMC MGIA 
co-cultures enhanced mycobacterial growth, whereas the addition 
of the iron chelator deferoxamine reduced it35. Taken together, 
these data indicate an association between Hb/iron and myco-
bacterial growth, likely via the heme iron uptake pathway45. 
This effect is particularly pertinent in preclinical models such 
as the macaque, where blood collections can perturb Hb levels. 
Indeed, while levels remained within the normal range for the 
species, we observed a significant decrease in Hb concentration 
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at 4 and 8 weeks relative to baseline following a fortnightly 
blood collection regimen in rhesus macaques35. Thus, while 
the direct whole blood MGIA may be appropriate to studies 
that use infrequent longitudinal sample collections or where 
variation in clinical parameters including Hb levels form 
part of the overall response, it may confound measures of 
vaccine-induced control of mycobacterial growth and reduce 
sensitivity to detect a vaccine response.
In humans, the direct PBMC MGIA demonstrated a stronger 
primary vaccine effect and greater reproducibility over 
repeated baseline bleeds compared with whole blood, most likely 
due to the evaluation of longitudinal PBMC samples in one 
batch30. Ability to batch samples in this way also improves logis-
tical feasibility and transferability, particularly to institutes 
without immediate access to a BACTEC MGIT instrument. 
Furthermore, the use of cryopreserved cells enables additional 
retrospective studies of samples from historical NHP vaccine 
studies for validation and exploratory work, thus reducing the 
number of animals used. We therefore focussed our assay 
development efforts on the PBMC compartment. Importantly, 
we previously reported a significant influence of penicillin- 
streptomycin (P/S) antibiotics on mycobacterial growth if 
included in the culture medium during thawing and the subsequent 
cell rest period for human cells30. Optimisation experiments 
using 1×106 cells from n=3 volunteers in duplicate and a BCG 
inoculum of ~800 CFU in the in-tube MGIA confirmed a 
pronounced inhibitory effect of P/S if present in the culture 
medium post-thawing but not pre-freezing (mean TTP with P/S 
pre-freezing and post-thawing = 262 hours, STDEV = 26; P/S 
post-freezing only = 281 hours, STDEV = 7.4; P/S pre-freezing 
only = 113 hours, STDEV = 4; no P/S = 109 hours, STDEV 
= 3.6). Although penicillin has no reported activity against 
mycobacteria, streptomycin is a broad-spectrum bactericidal drug 
used as a first-line treatment for TB46. Uptake of streptomycin 
into human cells does occur, where it is sequestered in lyso-
somes and redistributed into the cytosol and concentrated47. 
Therefore it is likely that, despite washing cells following the 
cell rest, residual or retained streptomycin remained present 
in the co-culture. We therefore recommend the use of P/S in the 
pre-freezing medium only.
4.1.2.2 Multiplicity of infection
We previously demonstrated that reducing the MOI by 
increasing cell number rather than reducing mycobacterial 
inoculum increases ability to detect a BCG vaccine induced 
response using the NHP direct MGIA37. This was consist-
ent with findings using both the mouse and human direct 
MGIAs29,32. We also showed that repeatability and ability to 
detect a vaccine induced response is improved by co-culturing in 
static 48-well plates compared with rotating screw-cap tubes37, 
again reflecting findings in other species29,34. Based on these 
observations, the limitations of cell availability, and to ensure 
consistency with the equivalent human assay29, we recommend 
the conditions of 3 × 106 cells co-cultured in 48-well plates 
with 500 CFU BCG as described in section 3.0. However, an 
alternative protocol using 1 × 106 cells in sealed, rotating 2ml 
screw-cap tubes has been successfully applied in humans, and 
used in the NHP model to demonstrate improved control of 
mycobacterial growth following M.tb infection29,36. Some research-
ers consider that the in-tube protocol may be applied where cell 
number is limiting and biological effects strong, and can be 
used to further dissect the mechanism of mycobacterial growth 
control29,48. Details of this alternative method and the associated 
protocol may be found in the report of optimisation and 
standardisation of the human direct MGIA29.
4.1.2.3 Serum
We recommend the addition of autologous time-point matched 
serum to co-cultures to resemble ex vivo conditions as 
closely as possible and ensure that any effects of vaccination 
mediated by serum factors are taken into account. We recently 
demonstrated that the addition of autologous serum contrib-
utes to improved control of mycobacterial growth following 
BCG vaccination in the human direct PBMC MGIA [Bitencourt 
et al. submitted49]. Using autologous serum also has the 
3Rs benefit of not using foetal bovine serum (FBS) which has 
ethical implications50. We titrated the serum concentration 
using in-tube human PBMC co-cultures (n=4), and found 
that mycobacterial growth was similar when adding 5, 10 or 
20% serum (mean TTP = 285, 257 and 316 hours respec-
tively), but increased when serum was at a concentration of 30% 
(TTP = 180 hours). While 5–20% is a standard serum concen-
tration for cell culture, 30% may be detrimental to cell viability, 
allowing mycobacteria to proliferate unchecked.
Due to limitations regarding the maximum blood volume per-
mitted for collection from macaques, plasma may be a more 
feasible alternative to serum. As specific antibodies are likely 
the main component of serum contributing to control of 
mycobacterial growth in the MGIA, we compared levels of 
PPD-specific IgM, IgG and IgA between serum and plasma 
from matched animals at baseline. In all cases there was a 
strong correlation, although serum contained modestly but 
significantly higher levels of specific antibodies at most 
time-points measured [Bitencourt et al. submitted49]. We 
therefore compared the use of autologous serum vs. autologous 
plasma in the direct NHP MGIA co-culture (n=7 animals), in 
which other components such as complement factors may also 
contribute to functional control of mycobacterial growth, and 
observed an intraclass correlation coefficient (ICC) of 0.58 
(moderate agreement). As shown by Bland-Altman analysis relat-
ing the difference between paired measurements to the mean 
of the pair, there was minimal bias between the two methods 
(mean bias = 0.025). Furthermore, all samples were within 
the 95% limits of agreement (the interval of 1.96 standard devia-
tions of the measurement differences either side of the mean 
difference), which extended from -0.20 (95% CI, -0.50 to 
-0.13) to 0.25 (95% CI, 0.18 to 0.55) log
10
 CFU (Figure 6). 
Although the sample size was small and there is some in inher-
ent intra-assay variability, this suggests that plasma may be 
substituted where serum is unavailable or limited in volume, but 
we do not recommend using the two samples interchangeably 
within a single experiment or direct comparison.
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The effect of heat inactivating serum was assessed by meas-
uring mycobacterial growth at the end of in-tube n=6 human 
PBMC co-cultures. Mycobacterial growth was lower when 
co-cultures contained serum that had been heat-inactivated 
compared with serum that had not been heat inactivated, 
but this was not statistically significant by Friedman with 
Dunn’s correction for multiple comparisons (Δ mean TTP 
= 24 hours; Friedman with Dunn’s correction for multiple 
comparisons, Figure 7). It has been reported that heat inacti-
vation of serum decreases uptake of mycobacteria into mono-
cytes due to the destruction of complement51. As monocytes 
provide the target host cell for mycobacterial survival and rep-
lication, a decrease in monocyte invasion may lead to decreased 
mycobacterial growth. Finally, we compared serum/plasma 
separated from blood collected in either serum clot-activator 
or Ethylenediaminetetraacetic acid (EDTA) vacutainers. Add-
ing plasma separated from an EDTA vacutainer to the MGIA 
co-culture resulted in significant inhibition of mycobacte-
rial growth (p=0.003, Δ mean TTP = 68 hours; Friedman with 
Dunn’s correction for multiple comparisons, Figure 7). EDTA 
has been shown to have anti-tubercular activity and has even been 
suggested for potential use in treatment of drug-resistant 
TB52. Based on these findings, we recommend that autologous 
serum/plasma should be added to a final concentration of 20%, 
should not be heat-inactivated and should not be collected 
in vacutainers containing EDTA.
4.1.3 Day 4 processing. At the end of the 96-hour co-culture 
period, cells are lysed to release intracellular mycobacteria. We 
previously compared mycobacterial recovery under 5 differ-
ent cell lysis conditions using the human in-tube direct PBMC 
MGIA: 1) none, 2) sterile water, 3) PBS with Tween 20, 4) 0.2% 
Saponin, and 5) 0.067% Sodium Dodecyl (lauryl) Sulfate (SDS) 
across three different sites. BCG recovery was comparable 
across conditions at all sites29. While the cell lysis step can 
thus be omitted for the in-tube protocol, it must be included in 
the recommended 48-well plate protocol to ensure that myco-
bacteria are released from monocytes that have adhered to 
the well surface; we suggest the use of sterile water to maximise 
transferability.
4.1.4 Characterisation of intra- and inter-assay reproduc-
ibility. We previously characterised the repeatability of the direct 
NHP MGIA at 3 different sites. The median CV between rep-
licate co-cultures was 2.69% (range 0.59 to 6.12%, n=8), 1.67% 
(range 0.78 to 8.52%, n=5) and 2.71% (range 0 to 7.33%, 
n=5) at sites 1, 2 and 3 respectively. The ICC values were 0.90 
(‘almost perfect’ agreement), 0.34 (‘fair’ agreement) and 0.95 
(‘almost perfect’ agreement) respectively37. A single sample 
set (n=8) was assayed on two separate occasions at the same 
site to assess inter-assay precision. The median CV between 
assay runs was 6.83% (range 2.13 to 7.76%) with an ICC value 
of 0.80 (‘substantial’ agreement). While there was a strong 
consistency agreement, mycobacterial growth was systemati-
cally higher (indicated by a shorter TTP) in run 2. The most likely 
cause is a difference in inoculum due to differences in titre or 
viability between mycobacteria stock vials. However, as shown 
by Bland-Altman analysis, the bias was not fully compensated 
by normalising growth using the direct-to-MGIT control (mean 
bias = 0.39). We thus recommend assaying all samples from 
different treatment groups or across a longitudinal time-course 
in a single batch. It should be noted that all samples between 
the two runs were within the 95% limits of agreement, which 
extended from 0.12 (95% CI, -0.19 to 0.21) to 0.66 (95% CI, 
0.58 to 0.97) log
10
 CFU37, but further work is required to 
achieve absolute agreement.
4.2 Validation studies
The biological relevance of the MGIA as a surrogate meas-
ure of vaccine efficacy can only be confirmed by comparing 
outcomes with levels of protection following in vivo mycobac-
terial challenge or infection. Similar assessments have been 
conducted of the malaria growth inhibition assay in relation 
to protection from controlled malaria infection in NHPs and 
humans15,53–56. This has previously been achieved for the human 
and murine direct MGIAs at the group level22,31,33,57. However, 
validation at an individual level would be more stringent given 
the variability in BCG-induced protection between individuals 
and animals58,59. We recently described an association between 
mycobacterial growth in the direct PBMC MGIA and 
outcome of in vivo intradermal BCG infection at the individual 
level in humans33. BCG was used in this study as a potential sur-
rogate challenge agent for virulent M.tb, which cannot ethically 
be used in human infection studies60. The NHP model provides 
an opportunity to validate the assay against direct measures of 
protection from M.tb as well as BCG infection, allowing greater 
confidence in the relevance of the human assay such that 
preclinical models may ultimately be replaced in some 
settings.
As previously reported, we used samples from BCG vacci-
nated NHPs across four different studies to evaluate biological 
validity of the NHP MGIA37. In the first study, there was a 
significant correlation between M.tb growth in the whole 
blood MGIA at the peak of response and the number of BCG 
CFU recovered from the axillary lymph nodes following 
in vivo BCG challenge. There was a more pronounced associa-
tion between MGIA vaccine response (post-vaccination growth – 
baseline growth) and lymph node CFU. MGIA vaccine response 
at the peak time-point also correlated with multiple measures 
of protection following in vivo M.tb challenge in a further two 
studies37. This suggests that the magnitude of vaccine response 
relative to baseline (which is akin to fold change and captures 
more information in a single measure) is a more representa-
tive measure of in vivo protection than absolute inhibition at 
a given time-point. This correlation between MGIA outcome 
and measures of protection from in vivo challenge with either 
BCG or M.tb at an individual animal level affords confidence 
that the assay is measuring a biologically meaningful response, 




One of the objectives when developing the direct MGIA was 
to provide an assay that was, technically and logistically, as 
simple as possible to maximise reproducibility and 
transferability28. In the absence of a validated correlate of 
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protection, we also chose not to include stimulation or expansion 
steps to avoid biasing, or over-representing certain aspects of, the 
immune response. We previously sought to transfer and har-
monise the protocol defined here to ensure that the 3Rs impact 
is maximised and that comparable information can be extracted 
from ongoing and future studies of different preclinical vac-
cine candidates across organisations. As recommended by Smith 
et al., we conducted side-by-side operator training at end-user 
institutes61, and then assessed reproducibility (variation between 
multiple determinations of a single sample analysed at differ-
ent laboratories or sites62) by conducting inter-site comparisons 
between sites 1 and 2 and sites 1 and 3 using two shared sample 
sets. Between sites 1 and 2, the median CV was 14.19% (range 
11.57 to 17.29%, n=7) with an intraclass correlation coefficient 
(ICC) value of 0.57 (‘moderate’ agreement). Between sites 1 
and 3, the median CV was 3.17% (range 0.39 to 8.62%, n=8) 
with an ICC of 0.83 (‘almost perfect’ agreement)37. The com-
parison between sites 1 and 2 resulted in lower inter-site 
reproducibility, which may have been due to the more homoge-
neous sample set used which had similar levels of growth control 
across animals. We therefore selected a sample set with a broader 
dynamic range for the comparison between sites 1 and 3, 
and observed a close mirroring in the pattern of control37.
Our reproducibility values were comparable to those reported 
for the human PBMC MGIA29 and were well within the 50% 
limit of acceptable variation suggested by Tuomela et al. for 
the measurement of a bacterial target in a cell-based assay62. 
However, we did observe a systematic difference in the site 
1–2 comparison. Again, normalising growth values using the 
corresponding direct-to-MGIT control did not fully compen-
sate for this bias and further work is required to achieve abso-
lute agreement37. However, all samples were within the 95% 
limits of agreement, which extended from -0.61 (95% CI, -0.89 
to -0.54) to -0.21 (95% CI, -0.27 to 0.07) log
10
 CFU for the site 
1–2 comparison and -0.26 (95% CI, -0.70 to -0.15) to 0.49 
(95% CI, 0.37 to 0.93) log
10
 CFU for the site 1–3 comparison. 
Importantly the delta between the highest and lowest values 
was consistent between sites, and given that the magnitude of 
vaccine response (post-vaccination growth – baseline growth) 
appears to be the most relevant measure as a surrogate of 
protective efficacy, systematic differences may be less 
problematic37. The delta between baseline and post-vaccination 
time-points, or between vaccinated and unvaccinated animals, 
should thus be considered in comparisons of vaccine efficacy 
measured at different sites rather than absolute growth values.
The main barrier to uptake of this assay by other potential 
end-users is the requirement for a BACTEC MGIT machine 
and the cost of associated reagents. While we recommend this 
quantification system as a faster, simpler, more sensitive and 
more objective alternative to CFU plating on solid agar, Kolibab 
et al. have demonstrated a highly significant linear inverse 
correlation between BACTEC MGIT TTP and CFU on solid 
agar following a 7 day MGIA using mouse splenocyte co-cultured 
with bone marrow macrophages63. It may therefore be possible 
to use traditional colony counting in resource-limited settings. 
That said, the BACTEC MGIT machine is a widely-used TB 
diagnostic tool available in most hospitals worldwide and 
many academic medical research groups have indirect access. 
Furthermore, using cryopreserved PBMC permits the batching 
of samples which improves logistical feasibility for those with 
limited MGIT access compared with whole blood assays, which 
must be run in real-time at multiple time-points. An additional 
potential barrier to uptake of MGIAs is access to high contain-
ment level facilities for the handling of virulent M.tb. For this 
reason, we focussed our optimisation work around the use of 
BCG as a surrogate agent of in vitro infection as discussed 
in section 4.1.1.
5.2 Translatability
The relative simplicity of the direct MGIA method described 
makes it highly translatable across host species and 
compartments28. We have demonstrated optimisation and appli-
cation of the assay using splenocytes31,32,43 and, more recently, 
lung cells64 from mice. Applying the assay in place of M.tb 
challenge experiments locally has downgraded the severity of 
many of our murine TB vaccine studies from ‘Moderate’ to 
‘Mild’ as vaccination is the only in vivo procedure required. Other 
groups have also reported use of the murine assay34,57. Attempts 
to adapt the assay for use in the bovine model have, however, 
been less successful65, suggesting that translation may not be 
straightforward in all cases. In humans, we have optimised 
and harmonised the direct MGIA as part of the FP7 European 
Research Infrastructures for Poverty Related Diseases 
(EURIPRED) consortium29, applied it to demonstrate a BCG 
vaccine effect30, and validated it against protection from in vivo 
experimental BCG infection33. Studies by our group and others 
demonstrate how the direct MGIA may be employed to address 
different aspects of TB research including clinical studies 
of TB patients44,48,66,67, coinfections68, and underlying immune 
mechanisms of protection48,69–73. Indeed, the direct NHP 
MGIA has also been applied to demonstrate improved control 
of mycobacterial growth following M.tb infection36, consistent 
with findings in recently M.tb-infected humans44,48. Beyond TB, 
we have recently adapted the assay for use with other patho-
gens including S. aureus and K. pneumoniae to explore the 
potential non-specific effects of BCG vaccination in humans 
[Wilkie M and Tanner R, unpublished data]. 
5.3 Measures of success/acceptance
Based on our experience of standardisation and harmonisation 
of the NHP MGIA, we recommend that repeatability between 
replicate co-cultures and precision between different runs 
of the same samples should be below 10% CV and above 0.5 
ICC. Ideally an inter-site comparison between the developer and 
end-user site should be conducted using a shared sample set, 
with a reproducibility cut-off of below 15% CV and above 0.5 
ICC. Bland-Altman analyses for both inter-assay and inter-site 
comparisons allowed us to define limits of agreement (as reported 
in section 4.1.5 and section 5.1), which may be considered esti-
mates of population parameters, although it should be noted 
that the systematic biases described will influence these 
values. Comparisons of standard curves from a common stock 
between sites would also aid confidence in initial assay trans-
fer. The ultimate test of acceptance is conducting the NHP 
MGIA alongside one or more in vivo mycobacterial infection 
stud(ies) and demonstrating a significant association between 
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outcomes. As BCG is currently the only licenced TB vaccine, 
ability to detect a BCG vaccine-induced response is the 
benchmark for assessing correlates of protection, and could 
be used in this context (using samples where BCG is known 
to have conferred protection in vivo). A more stringent meas-
ure would be correlating MGIA outcomes with measures of 
in vivo protection mediated by BCG and other TB vaccine 
candidates at an individual animal level, as we have previously 
described for BCG vaccination37.
5.4 Scientific and 3Rs benefits and impact
5.4.1 Scientific benefits. Broadly speaking, a reliable and vali-
dated MGIA for use with samples from immunised NHPs 
would permit high-throughput cost-effective evaluation of vac-
cine candidates, and down-selection of those going forward 
into in vivo efficacy testing; this would ultimately expedite the 
development of a much-needed effective TB vaccine. The direct 
MGIA also provides a tractable system for the assessment of 
immune mechanisms underlying the control of mycobacterial 
growth; manipulation of immune parameters in this way (e.g. cell 
depletions) is often not logistically or ethically feasible in vivo. 
Findings may further inform our understanding of protective 
immunity from TB and thus direct improved vaccine design as 
well as development of diagnostic and therapeutic tools. The 
NHP MGIA in particular offers the opportunity to biologically 
validate the assay through correlation with direct measures of 
protection from in vivo M.tb challenge on an individual ani-
mal basis. This is not possible using mice (where animals must 
be euthanised for the splenocyte MGIA and can therefore only 
be correlated by group) or humans (where M.tb challenge is 
not ethically viable). Such validation allows bridging to use 
in target species including humans where direct measures of 
protection cannot be obtained.
5.4.2 3Rs benefits. The process of early testing of TB vaccine 
candidates in NHP models could be refined by using the MGIA 
in place of in vivo infection with pathogenic M.tb. Furthermore, 
the number of NHPs used in TB vaccine testing and associated 
immunology studies could be reduced, as the MGIA allows:
a)    Testing of multiple conditions (for example differ-
ent mycobacterial clinical isolates and immunological 
mechanisms) using cells from a single group, rather 
than requiring multiple groups of animals.
b)    Down-selection of vaccine candidates at an early stage 
of development such that fewer go forward to in vivo 
efficacy testing.
Ultimately, biological validation in NHPs allows bridging of 
the assay to use in target species including humans which may 
replace the use of preclinical models in some settings.
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Section 2.4 – take care to include spaces between numbers and units e.g. 2mM should read 
2 mM throughout the method sections, in addition please take care to remain consistent 
with time notation; use of min, minutes, hr, hours, h are used interchangeably throughout 
the methods sections and graphical representations. Should addition of sodium pyruvate be 
included here as in Section 3.2? 
 
○
Section 3.1.2 – specifies sterile PBS, but Figure 2 describes PBS-Tw80. 
 
○
Section 3.1.9 – this describes using Miles and Misra spotting for the determination of CFU – 
Table 3 specifies the use of 60 mm petri dishes, is this correct? 3 x 20 ul spots on 60 mm 
plates is technically challenging without pre-drying of agar plates to ensure robust surface 
tension of dilution spots to prevent spreading. Guiding the reader to an appropriate 
reference of this CFU technique may assist those not familiar with Miles and Misra spotting 
for CFU counting. 
 
○
Figure 2 – please describe the significance or meaning of the red asterisk after BCG. 
 
○
Section 3.2.2 – please specify the concentrations used for L-glutamine and sodium pyruvate. 
 
○
Section 3.2. 7 – 25mM HEPES in underlined. 
 
○
Figure 3 – ensure centrifuge speeds are consistent with manuscript text, define R10 media. 
 
○
Section 3.2. 10 – PEN/STREP is capitalised. 
 
○
Section 3.2. 15 – should the added volume be made to 600 ul not 500 ul to remain 
consistent with other controls and samples? 
 
○
Figure 4 – ensure centrifuge speed notation is consistent with manuscript text. 
 
○
Section 4.0 Results – second sentence use of “outcomes” is not clear. 
 
○




Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use 
by others?
Yes
If any results are presented, are all the source data underlying the results available to 
ensure full reproducibility?
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Are the conclusions about the method and its performance adequately supported by the 
findings presented in the article?
Yes
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